Dermata Therapeutics (DRMA) Stock Price, News & Analysis

Company Overview

Dermata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for dermatological diseases and conditions. The company’s research programs are designed to address areas of significant unmet need in medical dermatology, including inflammatory and other common skin disorders.

Dermata’s lead product candidate has been DMT310, a topical treatment based on a proprietary technology derived from a freshwater sponge. The company has evaluated DMT310 for conditions including acne vulgaris and psoriasis, with development programs intended to assess its potential as a treatment for a range of skin diseases.

Dermata Therapeutics was founded in 2014 and is headquartered in San Diego, California. The company completed its initial public offering in 2021 and has primarily operated as a development-stage business, with its activities centered on advancing its dermatology product candidates through clinical development and regulatory review.

Key Stats

• Today's Range: $1.01 to $1.08
• 50-Day Range: $1.02 to $1.72
• 52-Week Range: $0.95 to $4.66
• Volume: 22,093 shs
• Average Volume: 22,308 shs
• Market Capitalization: $4.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Dermata Therapeutics Stock Analysis - MarketRank™

Dermata Therapeutics scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Dermata Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Dermata Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Dermata Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dermata Therapeutics is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dermata Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.69% of the float of Dermata Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dermata Therapeutics has a short interest ratio ("days to cover") of 3.61, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dermata Therapeutics has recently decreased by 29.61%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dermata Therapeutics does not currently pay a dividend.

Dividend Growth

Dermata Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Dermata Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Dermata Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.90% of the stock of Dermata Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

8.67% of the stock of Dermata Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Staples
• Industry: Personal Care Products
• Sub-Industry: Personal Care Products
• Current Symbol: NASDAQ:DRMA
• CIK: 1853816
• Web: www.dermatarx.com
• Phone: 858-800-2543
• Fax: N/A
• Employees: 9
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): ($4.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.56 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -166.66%
• Return on Assets: -130.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.81
• Quick Ratio: 2.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.19 per share
• Price / Book: 0.47

Miscellaneous

• Outstanding Shares: 4,020,000
• Free Float: 3,141,000
• Market Cap: $4.10 million
• Optionable: Not Optionable
• Beta: 0.66